Recent advances in management of Gout

QJM: An International Journal of Medicine

Volumn 105, Issue 5, 2012, Pages 407-417

  Suresh, E ^a   Das, P ^a  

^a KETTERING GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ASCORBIC ACID; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; ICE; INDOMETACIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ALCOHOL CONSUMPTION; DIET THERAPY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; GOUT; HUMAN; LOW DRUG DOSE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 84859992667     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr242     Document Type: Review

References (95)

1. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64:267-72.
2. Annemans L, Spaepan E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67:960-6.
3. Choi HK, Ford ES, Li C, Curhan G. Prevalance of metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57:109-15.
4. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54:2688-96.
5. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007; 46:1441-4.
6. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011; 12:103.
7. Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther 2011; [Epub ahead of print; 10 February 2011].
8. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Prac Rheumatol 2007; 3:443-9.
9. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12:223.
10. Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging 2011; 28:591-603.
11. Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965; 62:639-47.
12. Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. Cleve Clin J Med 2010; 77(Suppl. 2):S2-25.
13. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non steroidal anti-inflammatory drugs: network metaanalysis. BMJ 2011; 342:c7086.
14. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database Syst Rev 2006; 4:CD006190.
15. Dinarello CA. How interleukin-1b induces gouty arthritis. Arthritis Rheum 2010; 62:3140-4.
16. Torres R, Macdonald L, Croil SD, Reinhardt J, Dore A, Stevens S, et al. Hyperalgesia, synovitis, and multiple biomarkers of inflammation are suppressed by IL-1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009; 68:1602-8.
17. So A, de Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
18. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613-7.
19. So A, de Meulemeester M, Pikhlak A, Yucell AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064-76.
20. Schlesinger N, Mysler E, Lin HY, de Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70:1264-71.
21. Lin YH, Hsu HL, Huang YC, Lee M, Huang WY, Huang YC, et al. Gouty arthritis in acute cerebrovascular disease. Cerebrovasc Dis 2009; 28:391-6.
22. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003; 327:1275-6.
23. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312-24.
24. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17:301-4.
25. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel group, dose comparison colchicine study. Arthritis Rheum 2010; 62:1060-8.
26. Sarkozy J. Management of gout. N Engl J Med 1996; 334:1543.
27. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371:1854-60.
28. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout like arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007; 49:670-7.
29. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19:329-36.
30. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11:974-9.
31. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29:331-4.
32. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritides. J Clin Rheumatol 2006; 12:275-6.
33. Suresh E. Diagnosis and management of gout: a rational approach. Postgrad Med J 2005; 81:572-9.
34. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009; 48(Suppl. 2):ii9-ii14.
35. Jordan KM, Cameron JS, Snaith M, Zhang M, Doherty M, Seckl J, et al. British Society of Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007; 46:1372-4.
36. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40:245-9.
37. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56.
38. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63:412-21.
39. Robbins N, Koch SE, Tranter M, Rubinstein J. The history and future of probenecid. Cardiovasc Toxicol 2011; [Epub ahead of print; 22 September 2011].
40. Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002; 17:625-6.
41. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011; 377:165-77.
42. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6:30-8.
43. Edwards NL. Febuxostat: a new treatment for hyperuricemia in gout. Rheumatology 2009; 48(Suppl 2):ii15-ii19.
44. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol 2006; 46:88-102.
45. Becker MA, Schumacher HR, Jr, Wortmann RL, Macdonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450-61.
46. Schumacher HR, Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59:1540-8.
47. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009; 48:188-94.
48. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12:R63.
49. Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm 2011; 68:389-98.
50. Singh JA. Advances in gout: some answers, more questions. Arthritis Res Ther 2010; 12:136.
51. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 2007; 9:258-64.
52. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 2007; 34:1955-58.
53. Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60:59-68.
54. Reinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag 2010; 6:543-50.
55. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711-20.
56. Stein HB, Hasan A, Fox IH. Ascorbic acid-induced uricosuria. A consequency of megavitamin therapy. Ann Intern Med 1976; 84:385-8.
57. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med 2009; 169:502-7.
58. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol 2008; 35:1853-8.
59. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol 2006; 18:193-8.
60. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des 2005; 11:4133-8.
61. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011; 23:192-202.
62. Yu KH, See LC, Huang YC, Yang CH, Sun JH. Dietary factors associated with hyperuricemia in adults. Semin Arthritis Rheum 2008; 37:243-50.
63. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350:1093-103.
64. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363:1277-81.
65. Ghadirian P, Shatenstein B, Verdy M, Hamet P. The influence of dairy products on plasma uric acid in women. Eur J Epidemiol 1995; 11:275-81.
66. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336:309-12.
67. Choi JW, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59:109-16.
68. Choi HK, Curhan G. Coffee, tea and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007; 57:816-21.
69. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59:539-43.
70. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447-52.
71. Ho MC, Shi W, Rinaldo-Matthis A, Tyler PC, Evans GB, Clinch K, et al. Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci USA 2010; 107:4805-12.
72. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs 2010; 11:495-8.
73. Perez-Ruiz F, Dalbeth N, Urresola A, Miguel E, Schlesinger N. Gout. Imaging of gout: findings and utility. Arthritis Res Ther 2009; 11:232.
74. Wright SA, Filippucci E, McVeigh C, Grey A, McCarron M, Grassi W, et al. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis 2007; 66:859-64.
75. Schueller-Weidekamm C, Schueller G, Aringer M, Weber M, Kainberger F. Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007; 62:437-43.
76. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009; 68:1609-12.
77. Singh JA. Quality of life and quality of care for patients with gout. Curr Rheumatol Rep 2009; 11:154-160.
78. Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007; 25(6 Suppl. 47):114-9.
79. Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011; [Epub ahead of print; 1 July 2011].
80. Sundy JS. Gout management: let's get it right this time. Arthritis Rheum 2008; 59:1535-37.
81. Harold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11:R46.
82. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28:437-43.
83. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006; 33:104-9.
84. Zhang LY, Schumacher HR, Su HH, Lie D, Dinnella J, Baker JF, et al. Development and evaluation of a survey of gout patients concerning their knowledge about gout. J Clin Rheumatol 2011; 17:242-8.
85. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55:786-90.
86. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis 2010; 19:1331-6.
87. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate predicts rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460-8.
88. Kuzell WC, Seebach LM, Glover RP, Jackman AE. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone. Ann Rheum Dis 1966; 25(6 Suppl.):634-42.
89. Akkasilpa S, Osiri M, Deesomchok U, Avihingsanon Y. The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia. J Med Assoc Thai 2004; 87:1087-91.
90. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49:298-303.
91. Avram Z, Krishnan E. Hyperuricemia-where nephrology meets rheumatology. Rheumatology 2008; 47:960-4.
92. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-21.
93. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-19992. National Health and Nutrition Examination Survey. JAMA 2000; 283:2404-10.
94. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51-9.
95. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39:1227-33.